Intelligence · Clinical Pipeline
Ningbo Cancer Hospital Pipeline
All ClinicalTrials.gov programs at Ningbo Cancer Hospital — phase, modality, and trial IDs.
- Programs
- 69
Quick answer
Ningbo Cancer Hospital has 69 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
OXALIPLATIN, ETOPOSIDE, CISPLATIN, CALCIUM FOLINATE, CAPECITABINE, IRINOTECAN, PACLITAXEL, FLUOROURACIL, TRABECTEDIN, DOCETAXEL, IFOSFAMIDE, PACLITAXEL ALBUMIN-BOUND, DOXORUBICIN, MITOTANE, CARBOPLATIN, GEMCITABINE
Ningbo Cancer Hospital
Patients with dMMR/MSI (non-colorectal/non-endometrial) locally advanced or metastatic cancer
1 trial -
OXALIPLATIN, IRINOTECAN, Vectibix 20 mg/ml concentrate for solution for infusion, FOLINIC ACID, CALCIUM LEVOFOLINATE, FLUOROURACIL
Ningbo Cancer Hospital
RAS and B-RAF wild-type metastatic colorectal cancer. RAS and B-RAF mutation will be determined using circulating cell-free DNA (ccfDNA) by IntPlex method
1 trial -
OXALIPLATIN, PANITUMUMAB, Lonsurf 15 mg/6.14 mg film-coated tablets, Lonsurf 20 mg/8.19 mg film-coated tablets, BEVACIZUMAB, NIVOLUMAB, TRASTUZUMAB
Ningbo Cancer Hospital
Patients with pMMR/MSS metastatic adenocarcinoma of the colon or rectum or gastroesophageal cancer (lower esophagus, gastroesophageal junction and gastric) and with known dihydropyrimidine dehydrogenase (DPD) deficiency defined as plasma uracil concentration ≥16 ng/ml, who undergo first-line treatment
1 trial -
PACLITAXEL AHCL 6 mg/ml, solution à diluer pour perfusion, Erbitux 5 mg/mL solution for infusion, CARBOPLATINE HOSPIRA 10 mg/ml, solution injectable pour perfusion
Ningbo Cancer Hospital
Head and neck squamous cell carcinoma
1 trial -
PF-07248144, FULVESTRANT ZENTIVA 250 mg, solution injectable en seringue préremplie, PF-07248144
Ningbo Cancer Hospital
Adult patients with advanced hormone receptor positive (HR+), HER2- breast cancer after at least a first line of endocrine therapy combined with CDK4/6 inhibitor in the metastatic setting
1 trial -
Pemazyre 4.5 mg tablets
Ningbo Cancer Hospital
Recurrent or metastatic solid cancer harboring a FGFR1,2 ,3 fusion/rearrangement or activating mutation, outside of the approved indications for any selective FGFR inhibitor in France
1 trial -
Pluvicto 1 000 MBq/mL solution for injection/infusion
Ningbo Cancer Hospital
Clear Cell Renal Cell Carcinoma (ccRCC)
1 trial -
Precision Cells
Ningbo Cancer Hospital
Precision Cell Immunotherapy
1 trial -
Revlimid 25 mg hard capsules, Isatuximab, Dexamethasone Tablets 2 mg, Revlimid 15 mg hard capsules, Isatuximab, VELCADE 1 mg powder for solution for injection, Revlimid 10 mg hard capsules
Ningbo Cancer Hospital
Newly diagnosed Multiple Myeloma
1 trial -
Stivarga 40 mg film-coated tablets
Ningbo Cancer Hospital
Bone sarcoma
1 trial -
TRASTUZUMAB DERUXTECAN, SACITUZUMAB GOVITECAN
Ningbo Cancer Hospital
Patients with metastatic or locally advanced HER2-low triple-negative breast cancer and eligible to receive sacituzumab-govitecan and T-Dxd according to their indication.
1 trial -
TRASTUZUMAB, FULVESTRANT, EXEMESTANE, PERTUZUMAB, PERTUZUMAB, TRASTUZUMAB, PERTUZUMAB, TUKYSA 150 mg film-coated tablets, LETROZOLE, TUKYSA 50 mg film-coated tablets, TRASTUZUMAB, ANASTROZOLE
Ningbo Cancer Hospital
HER2+ metastatic breast cancer with isolated brain progression
1 trial -
TRASTUZUMAB, TRASTUZUMAB, TRASTUZUMAB EMTANSINE, TRASTUZUMAB, TRASTUZUMAB DERUXTECAN, PERTUZUMAB, TRASTUZUMAB EMTANSINE
Ningbo Cancer Hospital
Patients with HER2-positive locally advanced inoperable or metastatic breast cancer with disease controlled after 2 years of maintenance treatment with anti-HER2 targeted therapy
1 trial -
TUKYSA 50 mg film-coated tablets, TUKYSA 150 mg film-coated tablets
Ningbo Cancer Hospital
Non-resectable locally advanced or metastatic HER2-positive breast cancer
1 trial -
Tecentriq 1 200 mg concentrate for solution for infusion
Ningbo Cancer Hospital
Muscle-invasive bladder cancer
1 trial -
Tecentriq 1,200 mg concentrate for solution for infusion, EXL01, IMFINZI 50 mg/mL concentrate for solution for infusion., Avastin 25 mg/ml concentrate for solution for infusion., Tecentriq 840 mg concentrate for solution for infusion, IMJUDO 20 mg/ml concentrate for solution for infusion., Avastin 25 mg/ml concentrate for solution for infusion.
Ningbo Cancer Hospital
Hepatocellular carcinoma
1 trial -
Tevimbra 100 mg concentrate for solution for infusion
Ningbo Cancer Hospital
Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh B, ALBI grade 1 or 2 liver function, pretreated or not by tyrosine kinase inhibitors and not pretreated with immunotherapy.
1 trial -
Verzenios 50 mg film-coated tablets
Ningbo Cancer Hospital
High/intermediate risk hormone receptor (HR) positive/human epidermal growth factor receptor 2 (HER2) negative breast cancer patients with indication of neoadjuvant therapy.
1 trial -
Yondelis 1 mg powder for concentrate for solution for infusion, DOXORUBICINE ARROW 2 mg/ml, solution pour perfusion
Ningbo Cancer Hospital
Localized, resected, FIGO stage I (2018 classification), uterine leiomyosarcoma
1 trial -
Zejula 100 mg hard capsules, Zejula 100 mg film-coated tablets, JEMPERLI 500 mg concentrate for solution for infusion
Ningbo Cancer Hospital
metastatic or recurrent endometrial or ovarian carcinosarcoma
1 trial -
Zelboraf 240 mg film-coated tablets
Ningbo Cancer Hospital
Patients with metastatic or unresectable locally advanced malignancies harboring BRAF genomic alterations, the biological target of vemurafenib, and who are no more amenable to curative treatment
1 trial
Frequently asked questions
How many pipeline programs does Ningbo Cancer Hospital have?
69 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs